Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Background to Gilead's $21 Bln acquisition of Immunomedics

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 09, 2022 5:05pm

219 Views

Post# 34591095

RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics

April 08, 2022 - " In draft guidance, the National Institute of Health and Care Excellence has rejected Gilead Sciences’ Trodelvy for use against triple negative breast cancer (TNBC), saying it is too expensive for use by the National Health Service (NHS)."

“Given the lack of treatment options for people with this type of breast cancer, we’re very disappointed that its price means we can’t recommend it for use in the NHS at this point,” Helen Knight, interim director of medicines evaluation at NICE, said in a release."

Although sacituzumab govitecan (also called Trodelvy) increases how long people have before their disease gets worse and how long they live compared with chemotherapy, at its current price it is too expensive to be considered a cost-effective use of NHS resources.

The aim of treatment is to stop the disease getting worse, extend life, and maintain or improve quality of life for as long as possible.

[ With regards to the above referenced aim of treatment - these are the aims that ONCY's pelareorep + paclitaxel doublet combination and the pelareorep + paclitaxel + immune checkpoint inhibitor triplet cocktail have set out to acheive in metastatic breast cancers including TNBC.]

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?